Article
NRAS mutations in primary and metastatic melanomas of Japanese patients.
International journal of clinical oncology - 1 Jan 2014
Uhara Hisashi, Ashida Atsuko, Koga Hiroshi, Ogawa Eisaku, Uchiyama Aya, Uchiyama Ryuhei, Hayashi Koichi, Kiniwa Yukiko, Okuyama Ryuhei
Abstract excerpt
BACKGROUND: Characterization of the MAPK signaling pathway in melanoma has led to the development of MEK inhibitors for the treatment of NRAS-mutated melanoma. The success of molecular-targeted therapies underscores the need to identify mutations in target genes. Most of the current data on genetic mutations have been obtained from Caucasian melanoma patients, and screenings of Asian populations are limited....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.